TransCon CNP
Achondroplasia (infants 0-2)
Key Facts
About Ascendis Pharma
Ascendis Pharma applies its TransCon transient conjugation technology to transform established drugs into long-acting therapies with improved dosing convenience and potentially enhanced efficacy. The company has a robust pipeline in endocrinology rare diseases and oncology, with several Phase 2 and Phase 3 trials ongoing. With headquarters in Denmark and operations across Europe and the US, Ascendis has established partnerships in China and Japan to expand global reach of its innovative therapies.
View full company profileAbout Ascendis Pharma
Ascendis Pharma applies its TransCon transient conjugation technology to transform established drugs into long-acting therapies with improved dosing convenience and potentially enhanced efficacy. The company has a robust pipeline in endocrinology rare diseases and oncology, with several Phase 2 and Phase 3 trials ongoing. With headquarters in Denmark and operations across Europe and the US, Ascendis has established partnerships in China and Japan to expand global reach of its innovative therapies.
View full company profileAbout Ascendis Pharma
Ascendis Pharma applies its TransCon transient conjugation technology to transform established drugs into long-acting therapies with improved dosing convenience and potentially enhanced efficacy. The company has a robust pipeline in endocrinology rare diseases and oncology, with several Phase 2 and Phase 3 trials ongoing. With headquarters in Denmark and operations across Europe and the US, Ascendis has established partnerships in China and Japan to expand global reach of its innovative therapies.
View full company profile